Collagen Solutions PLC Hardman Issues Research Report
December 09 2015 - 2:00AM
RNS Non-Regulatory
TIDMCOS
Collagen Solutions PLC
09 December 2015
Hardman & Co issues research report on Collagen
Solutions
Solid interim results: First half results to 30(th) September
demonstrate clear progress against the Board's objective of
creating a business with at least a GBP100m valuation by 2020.
Proforma sales growth of 97%, driven by new customer contract wins
and by pipeline progress from existing customers' medical device
programmes. The potential for operations in China (via joint
venture) and the development of a new production facility for a
global device manufacturer are both in late stage discussions which
would underpin longer term growth, if successfully executed. The
long term pipeline continues to build with strategic
collaborations.
Please click here for the full report:
http://www.hardmanandco.com/system/files/research_papers/COS%20Dec%2015.pdf
To contact us: Contact: Dr Martin Hall
Hardman & Co mh@hardmanandco.com, Dr
11/12 Tokenhouse Mark Brewer mb@hardmanandco.com
Yard Telephone: +44 20 7929 3399
London Follow us on Twitter @HardmanandCo
EC2R 7AS
www.hardmanandco.com
About Hardman & Co: For the past 20 years Hardman has been
producing specialist research designed to improve investors'
understanding of companies, sectors, industries and investment
securities. Our analysts are highly experienced in their sectors,
and have often been highly rated by professional investors for
their knowledge. Our focus is to raise companies' profiles across
the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this
is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an
appointed representative of Capital Markets Strategy Ltd and is
authorised and regulated by the Financial Conduct Authority; our
FCA registration number is 600843. Hardman Research Ltd is
registered at Companies House with number 8256259.
Our research is provided for the use of the professional
investment community, market counterparties and sophisticated and
high net worth investors as defined in the rules of the regulatory
bodies. It is not intended to be made available to unsophisticated
retail investors. Anyone who is unsure of their categorisation
should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security.
Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABLBDDXUGBGUI
(END) Dow Jones Newswires
December 09, 2015 02:00 ET (07:00 GMT)
Healthcare Inv (LSE:HIO)
Historical Stock Chart
From Apr 2024 to May 2024
Healthcare Inv (LSE:HIO)
Historical Stock Chart
From May 2023 to May 2024